Suketu D. Desai

Suketu D. Desai, Ph.D. has 25+ years of experience in the Biologics and Pharmaceutical Industry. Suketu is Chief Technical Officer and Senior Vice President, Chemistry, Manufacturing and Controls, Regulatory CMC and Quality at Semnur Pharmaceuticals (acquired by Scilex Pharmaceuticals), Inc., (2015-current). Prior to Semnur, Suketu was Vice President of Biologics Development and Manufacturing for biologics drug substance and drug product, technical due diligence and commercial technical operations at Allergan, Inc. (2014-2015), which was acquired by Actavis, plc. Before Allergan, Suketu was a CMC consultant in 2013. Suketu was Vice President, Biotechnology Technical Operations for biologics drug substance and drug product, analytical, manufacturing and technical due diligence at Cephalon, Inc. (2010-2012), which was acquired by Teva Pharmaceuticals. During 2007-2010, Suketu was Ception Therapeutics, Inc., Vice President, Chemistry, Manufacturing and Controls (CMC) and Quality responsible for biologics drug substance and drug product development, analytical, manufacturing, quality, regulatory CMC and technical due diligence for business development. Ception was acquired by Cephalon (2010).